

Clinical Commissioning Policy: Hyperbaric oxygen therapy for diabetic lower limb ulceration (diabetic foot ulcer) (all ages)

NHS England Reference: 170120P



NHS England INFORMATION READER BOX**Directorate**

Medical	Operations and Information	Specialised Commissioning
Nursing	Trans. & Corp. Ops.	Commissioning Strategy
Finance		

Publications Gateway Reference: 07603

Document Purpose	Policy
Document Name	Hyperbaric oxygen therapy for diabetic lower limb ulceration (diabetic foot ulcer) (all ages)
Author	Specialised Commissioning Team
Publication Date	12 April 2019
Target Audience	CCG Clinical Leaders, Care Trust CEs, Foundation Trust CEs , Medical Directors, Directors of PH, Directors of Nursing, NHS England Regional Directors, NHS England Directors of Commissioning Operations, Directors of Finance, NHS Trust CEs
Additional Circulation List	
Description	Not for routine commissioning
Cross Reference	
Superseded Docs (if applicable)	
Action Required	
Timing / Deadlines (if applicable)	
Contact Details for further information	england.specialisedcommissioning@nhs.net

Document Status

This is a controlled document. Whilst this document may be printed, the electronic version posted on the intranet is the controlled copy. Any printed copies of this document are not controlled. As a controlled document, this document should not be saved onto local or network drives but should always be accessed from the intranet.

Clinical Commissioning Policy: Hyperbaric oxygen therapy for diabetic lower limb ulceration (diabetic foot ulcer) (all ages)

First published: April 2019

**Prepared by NHS England Specialised Services Clinical Advisory Group on
Hyperbaric Oxygen Therapy**

Published by NHS England, in electronic format only.

Contents

Policy Statement	5
Equality Statement	5
Plain Language Summary	5
1 Introduction	7
2 Definitions	9
3 Aims and Objectives	9
4 Epidemiology and Needs Assessment	10
5 Evidence Base	10
6 Criteria for Commissioning	13
7 Patient Pathway	13
8 Governance Arrangements	13
9 Mechanism for Funding	13
10 Audit Requirements	13
11 Documents which have informed this Policy	13
12 Date of Review	13
References	14

Policy Statement

NHS England will not routinely commission hyperbaric oxygen therapy for diabetic lower limb ulceration in accordance with the criteria outlined in this document.

In creating this policy NHS England has reviewed this clinical condition and the options for its treatment. It has considered the place of this treatment in current clinical practice, whether scientific research has shown the treatment to be of benefit to patients, (including how any benefit is balanced against possible risks) and whether its use represents the best use of NHS resources.

Equality Statement

Promoting equality and addressing health inequalities are at the heart of NHS England's values. Throughout the development of the policies and processes cited in this document, we have:

- given due regard to the need to eliminate discrimination, harassment and victimisation, to advance equality of opportunity, and to foster good relations between people who share a relevant protected characteristic (as cited under the Equality Act 2010) and those who do not share it; and
- given regard to the need to reduce inequalities between patients in access to, and outcomes from healthcare services and to ensure services are provided in an integrated way where this might reduce health inequalities.

Plain Language Summary

About Diabetic Foot Ulcer

A diabetic foot ulcer is an open wound or sore on the skin that is slow to heal (NHS Choices, 2016). People with diabetes mellitus are at increased risk of foot ulceration. Diabetes can reduce the blood supply to feet and cause a loss of feeling known as peripheral neuropathy (NHS Choices, 2015). This can mean foot injuries do not heal well, and a person may not notice if their foot is sore or injured.

About current treatments

The usual treatment of diabetic foot ulcers requires a team of health care professionals working together including foot and diabetic specialists. Treatment options include close monitoring of the ulcer, the use of antibiotic medicines, caring for the wound, and removing dead tissue. A treatment to help restore blood flow to the foot called revascularisation is also usually considered (National Institute for Health and Care Excellence 2015).

About the treatment

In addition to the standard care for diabetic foot ulcer, Hyperbaric oxygen therapy (HBOT) has been suggested as a potential additional therapy in cases where the normal treatment has failed to heal the wound. HBOT involves the inhalation of pure oxygen at a pressure higher than normal atmospheric pressure, usually 2 to 3 atmospheres absolute (ATA). During HBOT, the patient is in a pressure chamber, and when used for the treatment of diabetic foot ulcers, this is usually for 45 to 120 minutes on most days for several weeks.

What we have decided

NHS England has carefully reviewed the evidence to treat diabetic lower limb ulceration with hyperbaric oxygen therapy. We have concluded that there is not enough evidence to make the treatment available at this time.

1 Introduction

About diabetic lower limb ulceration (diabetic foot ulcers)

People with diabetes mellitus are at increased risk of foot ulceration. The ulcers are multifactorial, often caused or exacerbated by diabetic peripheral neuropathy and angiopathy. Diabetic neuropathy diminishes perception of pain, so that minor damage, such as localised pressure caused by unsuitable shoes, abnormal biomechanical stress or open wounds, is often not noticed. This makes early treatment difficult and makes the development of a foot ulcer more likely. Poor circulation because of diabetic vessel damage, leads to faster tissue breakdown and impairs resistance to infection, and ulcer healing (Schaper et al., 2012).

Current treatment

Standard treatment of diabetic foot ulcers requires a multidisciplinary team comprising a podiatrist, an orthotist, a specialised nurse and a diabetologist. Treatment options include close monitoring, intensive systemic antibiotic therapy, wound dressings and removal of dead tissue (debridement). Revascularisation is also usually considered (National Institute for Health and Care Excellence 2015).

Proposed Intervention

In Hyperbaric oxygen therapy (HBOT) patients receive 100% oxygen inside a pressurised treatment chamber (Hoggan & Cameron, 2014). HBOT involves the inhalation of pure oxygen at a pressure higher than normal atmospheric pressure, usually 2 to 3 atmospheres absolute (ATA). During HBOT, the patient is in a pressure chamber, and when used for the treatment of diabetic foot ulcers, this is usually for 45 to 120 minutes on most days for several weeks.

Side effects of HBOT are mostly infrequent and most often completely reversible. Reversible myopia, due to oxygen toxicity on the lens, is the commonest side effect and can last for weeks or months. Epileptic fits are rare and usually cause no permanent damage. A suggested carcinogenic effect of hyperbaric oxygen has not been substantiated in extensive studies (Leach, Rees & Wilmshurst, 1998). Irreversible serious harm or death is rare. Fire in the chamber is the most common cause of death and has been described in units with poor regulation and inadequate supervision. There have been no reports of fire in a UK therapeutic chamber in the past 50 years. Table 1 provides a summary of risks.

	UHMS 2018/ Camporesi 2014	UHMS 2018	Leach et al 1998	Hadanny 2016		
	% of patients			% of patients	Incidence per HBO session	Comments
Subjective barotrauma				3.4	174:100,000	
Symptomatic reversible barotrauma			15-20			
Objective middle ear barotrauma				9.2	410:100,000	
Sinus squeeze				0.7	27:100,000	
Hypoglycaemia				0.4	17:100,000	
Seizures			1-2	0.3	11:100,000	Usually cause no permanent damage
	0.01 to 0.03					Elective treatments
	1.8					Carbon monoxide poisoning
		0.6				Decompression illness
Dizziness/weakness				1.5	57:100,000	
Claustrophobia	2			0.3	11:100,000	
Chest pain				0.9	35:100,000	
Pulmonary barotrauma during decompression	Rare					
Pulmonary oedema		Rare				
Dyspnoea			15-20	0.3	13:100,000	
Visual changes	69		≤20	0.3		Can last for weeks or months
	96					Extremely prolonged treatment series
New onset cataracts	47					Extremely prolonged treatment series

2 Definitions

Adjuvant treatment: a treatment carried out in addition to normal treatment.

Atmospheres absolute (ATA): a measurement used to describe atmospheric pressure; one ATA is roughly equivalent to sea level atmospheric pressure.

Barotrauma: damage to the ear or other gas-filled spaces in the body caused by changes in pressure.

Debridement: surgical removal of dead tissue.

Diabetic peripheral neuropathy: nerve damage caused by chronically high blood sugar in diabetes. It leads to numbness, loss of sensation, and sometimes pain in the feet, legs, or hands. It is the most common complication of diabetes.

Haemorrhage: an escape of blood from a broken blood vessel.

Metatarsals: a group of five long bones in the foot.

Myopia: near-sightedness (close objects look clear but distant objects appear blurred).

Placebo treatment: fake (or dummy) treatment given to patients in the control group of a clinical trial. It is indistinguishable from the actual treatment (which is given to patients in the experimental group). The aim is to determine what effect the experimental treatment has had - over and above any placebo effect caused because someone has had (or thinks they have had) care or attention.

Pulmonary oedema: excess accumulation of fluid in the lungs.

Refractory Ulcers: ulcers that are unresponsive to standard care.

Revascularisation: a surgical procedure to help restore blood flow to an area of the body.

Ulceration: the formation of a break on the skin or on the surface of an organ.

3 Aims and Objectives

This policy considered: the evidence underpinning the use of HBOT for diabetic lower limb ulceration (diabetic foot ulcers).

The objectives were to:

- consider whether, in the management of diabetic lower limb ulceration (diabetic foot ulcers) the evidence base supports the addition of HBOT as a routine adjuvant treatment;
- the evidence base identifies the place of HBOT in the care pathway;
- there is evidence that HBOT is cost effective when used in this way.

4 Epidemiology and Needs Assessment

The annual incidence of foot ulcers among people with diabetes has been estimated at between 2.5% and 10.7%, and the annual incidence of amputation is 0.25% to 1.8% (Boulton, 2008). This translates into between 58,470 and 250,252 potential cases of foot ulcers in England (PHOF, 2017).

Regular foot examination, patient education, simple hygienic practices, provision of appropriate footwear, and prompt treatment of minor injuries can decrease ulcer occurrence by 50% and eliminate the need for major amputation in non-ischaemic limbs (Larsson et al., 1995; Lavery, Wunderlich, & Tredwell, 2005).

The majority (60–80%) of foot ulcers will heal, while 10–15% of them will remain active, and 5–24% of them will finally lead to limb amputation within a period of 6–18 months after the first evaluation (Alexiadou & Doupis, 2012). True estimates of the numbers of patients with refractory ulcers are difficult to make because of the variation in ‘standard’ care in clinical practice.

5 Evidence Base

NHS England has concluded that there is not sufficient evidence to support the routine commissioning of this treatment for the indication.

Summary of Evidence

NHS England commissioned a review of the published evidence on the use of HBOT treatment for patients with diabetic lower limb ulceration (diabetic foot ulcer). To aid in the search for clinically relevant literature, experts in the field of HBOT guided the development of a Population, Intervention, Comparison, Outcome (PICO) framework. Key findings were:

- This evidence review found four randomised controlled trials and one cost-utility analysis.
- Two trials compared HBOT plus standard care with standard care only, and two compared HBOT plus standard care with sham HBOT plus standard care.
- They reported results in three categories: amputation or the emergence of indications for amputation, partial or complete ulcer healing and adverse effects of treatment.
- Fedorko et al 2016 conducted a double-blind randomised trial using air at slightly above atmospheric pressure as a sham alternative to HBOT. The authors reported no effect of HBOT on rates of meeting vascular surgical criteria for major amputation (95% CI 0.37 to 2.28, $p = 0.846$) or of recommendation of major or minor amputation (95% CI 0.52 to 2.43, $p = 0.771$) among their 103 participants.

Major amputation was defined as a procedure below the knee or at the level of the metatarsals; minor amputations were at the level of the toes.

- Fedorko et al (2016) reported that at 12 weeks after starting HBOT, there was no significant effect of HBOT on wound size, the rate at which the wound edge advanced, the results of a wound assessment tool or the proportion of wounds that healed.
- In another double-blinded study, Löndahl et al (2010) randomised 94 participants between HBOT and hyperbaric air, both at 2.5 atmospheres. The authors reported rates of complete healing of the index ulcer of 52% in the HBOT group and 29% in the placebo group ($p = 0.03$). The longer follow up period of this study (1 year compared to 12 weeks in Fedorko et al) enabled the authors to report rates of death and actual major (above the ankle) and minor amputation. There were 3 major amputations (above the ankle) in the HBOT group and one in the control group, along with 4 minor amputations in each group. However, the statistical significance of these differences was not tested. By contrast, Duzgun et al's (2008) unblinded trial with 100 participants did not use a placebo treatment. These authors reported that more participants treated with HBOT had ulcers that healed (66% vs 0%, $p < 0.05$) or were treated with a graft or flap (8% vs 0%, $p < 0.05$), while fewer had an amputation (distal: 8% vs 48%, $p < 0.05$; proximal: 0% vs 34%, $p < 0.05$).
- Ma et al (2013) reported a smaller, less reliable, unblinded study, with only 36 participants. They reported the same rates of completed ulcer healing with and without HBOT. Ulcer size was reported as reducing faster after HBOT, though not to the extent that significantly more ulcers had healed by the end of the study.
- Participants who underwent HBOT in Fedorko et al's (2016) trial reported 24 adverse events which had not been specifically solicited by the researchers, significantly more than the five events reported by the participants who had a sham treatment. Rates of reporting of solicited adverse events were similar in the two groups. Löndahl et al (2010) reported similar rates of adverse events in the two arms of their trial. The most common adverse events in these two trials included barotrauma, inability to equalise middle ear pressures and episodes of hypo- or hyper-glycaemia. Ma et al (2013) reported no adverse events in either arm of their trial.
- Fedorko et al (2016) reduced the risk of observer bias by the use of a placebo treatment with hyperbaric air, and double-blinding. The pressure of the air (125 kPa / 1.23 ATA) was asserted to be too low to have an adverse effect on wound healing. The authors argue that this was substantiated by the higher rate of adverse reactions in the intervention arm. The randomisation resulted in different proportions of participants with potential confounders in each arm: for example, the HBOT group participants had had their index ulcer for less time than those in

the control group, but had had diabetes for longer. The authors reported no benefit from HBOT as assessed at 12 weeks.

- Löndahl et al (2010) also used a double-blind design, with control participants receiving placebo hyperbaric air. Randomisation in this trial resulted in no important differences between participants allocated to the two arms. Fedorko et al. suggest that the placebo pressure used by Löndahl et al (2.5 ATA vs 1.23 ATA in Fedorko) might be high enough to create a risk of adverse effects on ulcer healing in the control arm. However, neither the magnitude, nor the likelihood of this risk was estimated by Fedorko et al.
- The other two trials reported benefit from HBOT. However, both were at material risk of bias because the participants and the researchers were aware of whether HBOT had been used; this is a plausible explanation for their discrepant results.
- There are some additional concerns about Duzgun et al (2008). The authors appear to suggest that there may have been significant confounding, though the nature, extent and impact of this are not reported.
- Furthermore, none of 50 control participants' ulcers in Duzgun et al's (2008) trial were healed after 92 weeks of treatment. This is inconsistent with the other trials, despite the participation of people with Wagner grade 2 ulcers in all trials, and calls into question the effectiveness of standard care in this trial. Poor standard care would make this trial not generalisable to the NHS.
- Adverse events appear more common after HBOT.
- We found one cost-utility study. Chuck et al (2008) reported that HBOT was both more effective and less expensive than standard care.
- Chuck et al's (2008) analysis is of limited relevance and reliability.
- It used estimates of the effectiveness of HBOT from a study published in 2003 (Guo et al 2003), which predates the three randomised trials in this rapid evidence review. The model's assumptions about the effectiveness of HBOT are incompatible with this more recent evidence, which is derived from more reliable studies. Chuck et al (2008) themselves noted that the clinical data that they used were "*limited*". The costs are based on the Canadian health care system in 2008, and may be materially different from those in the NHS. The authors admitted that their data were not "*of high quality.*" They went on to note "*Cost data for HBOT were based on data from only a few centers, and reporting was not standardized*".

Conclusion

There is inconsistent evidence that HBOT is effective in the treatment of diabetic foot ulcers. Taken as a whole, the evidence is insufficient and so does not support HBOT's routine use in the NHS for this indication. Two of the trials reporting benefit were at risk of placebo effects and observer bias because they were unblinded; they

are unreliable. Of the two double-blind trials, one reported no benefit from HBOT as judged at 12 weeks and a second reported benefit observed at 52 weeks. The study reporting benefit used a higher pressure for the sham treatment than was used for the sham treatment in the study reporting no benefit.

There would be value in a further double-blind trial of HBOT for this indication, with a control similar to that used in Fedorko et al (2016).

6 Criteria for Commissioning

Not applicable.

7 Patient Pathway

Not applicable.

8 Governance Arrangements

Not applicable.

9 Mechanism for Funding

Not applicable.

10 Audit Requirements

Not applicable.

11 Documents which have informed this Policy

This document updates and replaces the published policy - NHS England policy: Hyperbaric Oxygen Therapy April 2013

<https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2013/10/d11-p-a.pdf>

12 Date of Review

This document will be reviewed when information is received which indicates that the policy requires revision.

References

- Alexiadou K, Doupis J. 2012. Management of Diabetic Foot Ulcers. *Diabetes Therapy*. 3(1):4. doi:10.1007/s13300-012-0004-9.
- Boulton JM 2008. The diabetic foot - an update. *Foot and Ankle Surgery*, 14, 120-4.
- Camporesi E. 2014. Side Effects of HBO2 Therapy. *Undersea and Hyperbaric Medicine*. 41(3): 253-257
- Chuck AW, Hailey D, Jacobs P, Perry DC. 2008. Cost-effectiveness and budget impact of adjunctive hyperbaric oxygen therapy for diabetic foot ulcers. *International Journal of Technology Assessment in Health Care*, 24, 178-83.
- Duzgun AP, Satir HZ, Ozozan O, Saylam B, Kulah B, Coskun F 2008. Effect of hyperbaric oxygen therapy on healing of diabetic foot ulcers. *J Foot Ankle Surg*, 47, 515-519.
- Fedorko L, Bowen JM, Jones W, Oreopoulos G, Goeree R, Hopkins RB, O'Reilly DJ 2016. Hyperbaric oxygen therapy does not reduce indications for amputation in patients with diabetes with nonhealing ulcers of the lower limb: A prospective, double-blind, randomized controlled clinical trial. *Diabetes Care*, 39, 392-9.
- Guo S, Counte MA, Gillespie KN, Schmitz H 2003. Cost-effectiveness of adjunctive hyperbaric oxygen in the treatment of diabetic ulcers. *Int J Technol Assess Health Care*, 19, 731-737.
- Hadanny A, Meir O et al. 2016. The safety of hyperbaric oxygen treatment – retrospective analysis in 2,334 patients. *Undersea and Hyperbaric Medicine* 43 (2): 113-122
- Hoggan BL, Cameron AL. 2014. Systematic review of hyperbaric oxygen therapy for the treatment of non-neurological soft tissue radiation-related injuries. *Support Care Cancer* 22: 1715-1726.
- Larsson J, Apelqvist J, Agardh CD, Stenström A. 1995. Decreasing incidence of major amputation in diabetic patients: a consequence of a multidisciplinary foot care team approach? *Diabet Med*. 12:770–776. doi: 10.1111/j.1464-5491.1995.tb02078.x.
- Lavery LA, Wunderlich RP, Tredwell JL. 2005. Disease management for the diabetic foot: effectiveness of a diabetic foot prevention program to reduce amputations and hospitalizations. *Diabetes Res Clin Pract*. 70:31–37. doi: 10.1016/j.diabres.2005.02.010.
- Leach RM, Rees PJ, Wilmschurst P. 1998. Hyperbaric oxygen therapy. *BMJ: British Medical Journal*. 317(7166):1140-1143.
- Löndahl M, Katzman P, Nilsson A, and Hammarlund C. 2010. Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. *Diabetes Care* 33: 998-1003.

Ma L, Li P, Shi Z, Hou T, Chen X, Du J. 2013. A prospective, randomized, controlled study of hyperbaric oxygen therapy: effects on healing and oxidative stress of ulcer tissue in patients with a diabetic foot ulcer. *Ostomy/wound management*, 59, 18-24.

National Institute for Health and Care Excellence. 2015. Diabetic foot problems: prevention and management. NICE guideline 19, August 2015. <https://www.nice.org.uk/guidance/ng19> accessed 26 May 2017.

NHS Choices. 2016. How to look after your feet if you have diabetes. [online] Available at: <https://www.nhs.uk/Livewell/fothealth/Pages/Diabetesandfeet.aspx> [Accessed 22 Dec 2017].

NHS Choices. 2015. Peripheral Neuropathy. [online] Available at: <https://www.nhs.uk/conditions/peripheral-neuropathy/complications/> [Accessed 22 Dec 2017].

(PHOF) Public Health Outcomes Framework. Diabetes: QOF Prevalence (17+). Available: <https://fingertips.phe.org.uk/>

Schaper NC, Andros G, Apelqvist J, Bakker K, Lammer J, Lepantalo M, Mills JL, Reekers J, Shearman CP, Zierler RE & Hinchliffe RJ. 2012. Diagnosis and treatment of peripheral arterial disease in diabetic patients with a foot ulcer. A progress report of the International Working Group on the Diabetic Foot. *Diabetes/Metabolism Research and Reviews*, 28(Suppl 1), 218-24.

Undersea and Hyperbaric Medical Society website - <https://www.uhms.org/2-side-effects.html> accessed 23 April 2018